{
    "relation": [
        [
            "",
            "MK0518 400 mg b.i.d.",
            "KALETRA\u2122 400/100 mg b.i.d."
        ],
        [
            "Description",
            "MK0518 400 mg, which can be taken by mouth (PO) twice a day (b.i.d.), approximately 12 hours (10 to 14 hours) apart without regard to food, and placebo to KALETRA\u2122 , which can be taken by mouth (PO) twice a day (b.i.d.), approximately 12 hours (10 to 14 hours) apart without regard to food",
            "KALETRA\u2122 400/100 mg, which can be taken by mouth (PO) twice a day (b.i.d.), approximately 12 hours (10 to 14 hours) apart without regard to food, and placebo to MK0518 , which can be taken by mouth (PO) twice a day (b.i.d.), approximately 12 hours (10 to 14 hours) apart without regard to food"
        ]
    ],
    "pageTitle": "MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00443729?sect=Xk015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042982502.13/warc/CC-MAIN-20150728002302-00097-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 842324183,
    "recordOffset": 842305747,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{2439=2008}",
    "textBeforeTable": "Reporting Groups HIV-seropositive patients who were \u226518 years old, had documented HIV RNA <50 copies/mL for at least 3 months, had been on a KALETRA\u2122-based regimen for at least 3 months without a change in background antiretroviral therapy, and had no documentation of HIV RNA >50 copies/mL for at least 3 months. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Phase III; First Patient In: 11-Jun-2007; Last Patient Last Visit for Week 24 (primary endpoint): 17-Oct- 2008 34 Sites (US, Peru, Brazil, Colombia, Mexico, South Africa, Thailand, India, and Australia). Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Comparator: raltegravir Drug: Comparator: placebo Drug: Comparator: lopinavir (+) ritonavir",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 MK0518 400 mg b.i.d. \u00a0 \u00a0 KALETRA\u2122 400/100 mg b.i.d. \u00a0 STARTED \u00a0 \u00a0 176 \u00a0 \u00a0 179 \u00a0 Treated \u00a0 \u00a0 176 \u00a0 \u00a0 178 \u00a0 COMPLETED \u00a0 \u00a0 166 \u00a0 \u00a0 172 \u00a0 NOT COMPLETED \u00a0 \u00a0 10 \u00a0 \u00a0 7 \u00a0 Never Treated \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 Lack of Efficacy \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 4 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}